The IRA was introduced in 2022 and aims to curb inflation by allowing Medicare to negotiate prices and rebates for certain drugs. Credit: designer491 via
Santhera’s Agamree is indicated for patients aged four years and older with Duchenne muscular dystrophy (DMD). Credit: JohnnyGreig via Getty Images. Swiss biotech Santhera Pharmaceuticals
Rising drug prices remain a contentious issue in the US. Credit: Malte Mueller via Getty Images. At the 2025 JP Morgan Healthcare Conference, GoodRx’s recently
The partnership centres on two of Regenxbio’s gene therapies, RGX-121 and RGX-111. Credit: Jinda Noipho via Getty Images. Regenxbio has entered into a strategic collaboration
Lilly plans to share its full Q4 2024 results on 6 February 2025. Credit: JHVEPhoto via Getty Images. Eli Lilly has announced a $400m reduction
Daiichi Sankyo has exclusive rights to further develop and commercialise gatipotuzumab as an antibody-drug conjugate (ADC). Image Credit: Photographer: Kentaro Takahashi/Bloomberg via Getty Images Daiichi
T-cell engagers are a class of immunotherapies that direct T cells to recognise and eliminate cancer cells. Credit: skynesher via Getty Images. US-based Normunity has
Sage emphasised that there is no certainty the proposal from Biogen will result in a transaction. Credit: skynesher via Getty Images. Biogen has made an
The deal includes an upfront payment of $1bn and an additional $150m tied to regulatory milestones. Credit: Bloomberg via Getty Images. GSK has announced a
A2 Bio has two ongoing Phase I/II clinical trials investigating two of its CAR-T programmes. Credit: THOMAS COEX via Getty Images. US-based biotech company A2